Immunotherapy before standard treatment for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of two drugs (pembrolizumab and MRG003) given before standard treatment for nasopharyngeal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes, and it may be an option for patients whose cancer has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been diagnosed with stage III to IVa nasopharyngeal cancer (not the T3N0 subtype).
- Your tumor must test positive for two markers: EBER (Epstein-Barr virus) and EGFR (a protein on the cell surface).
- You have not had immunotherapy (like PD-1/PD-L1 inhibitors) before, and you have not had treatment that targets EGFR.
- Your cancer has not spread to distant parts of the body like the lungs, liver, or bones.
- You are in generally good health (able to do daily activities, ECOG 0 or 1).
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial tests a combination of two drugs—an investigational antibody that targets cancer cells (MRG003) and a chemotherapy pill (capecitabine)—along with an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back but hasn't spread. The goal is to see if this approach can help control the cancer.
This trial studies a drug called MRG003 combined with another therapy that boosts the immune system to fight cancer. It aims to see if this combination can shrink tumors or slow the growth of nasopharyngeal cancer that has returned or spread.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests whether combining an experimental antibody-drug conjugate (MRG003) with an immunotherapy (pucotenlimab) works better than standard chemotherapy for people with nasopharyngeal cancer that has come back or spread. If you have tried at least one prior treatment and are generally in good health, you may be able to join.
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.